The acceptance of two clinical abstracts for presentation at a prestigious conference like AACR highlights the progress and potential of ALX Oncology's drug evorpacept. This could increase investor confidence and interest in the company, potentially leading to a positive impact on the stock price in the short term. The focus on significant diseases such as B-cell non-Hodgkin lymphoma and myelodysplastic syndrome further emphasizes the importance of the drug's development.